ライフサイエンスコーパス: neuropsychiatry

1 erview (schedules for clinical assessment in neuropsychiatry).

2 ine-related psychomotor slowing in geriatric neuropsychiatry.

3 tinnitus patient falls within the purview of neuropsychiatry.

4 plications in neuroscience, pharmacology and neuropsychiatry.

5 ic opportunities in behavioral neurology and neuropsychiatry.

6 sidered promising drug targets in cancer and neuropsychiatry.

7 asingly important target for therapeutics in neuropsychiatry and contributes to cognitive dysfunction

8 scientific psychopathology, namely cognitive neuropsychiatry and how it relates more broadly to imagi

9 rotransmitters are of as intense interest to neuropsychiatry and neurology as dopamine, yet existing

10 ing the Schedules for Clinical Assessment in Neuropsychiatry and the Maudsley Assessment of Delusions

11 Advances in developmental neuropsychiatry and the mental health needs of people wi

12 se in serotonin neurobiology, neurotoxicity, neuropsychiatry, and pulmonary medicine and evaluated fo

13 sk-associated genes that interact with known neuropsychiatry-associated genes via gene interaction ne

14 ine a principled pathway toward personalized neuropsychiatry based on dynamical systems theory and AI

15 to cardiovascular disease, endocrinology and neuropsychiatry by screening an average of 114 independe

16 al mechanistic level, and that computational neuropsychiatry can ultimately be leveraged to provide n

17 the individual level will push the field of neuropsychiatry forward in developing efficacious person

18 ctions within the context of a computational neuropsychiatry framework.

19 REporting Machine Learning Investigations in Neuropsychiatry (GREMLIN), for designing and reporting s

20 Quantitative neuropsychiatry has provided increasingly precise descri

21 The long anticipated 'genetic revolution' in neuropsychiatry has yet to have an impact on the practic

22 Neuropsychiatry has yet to surmount the fundamental chal

23 and research findings in both immunology and neuropsychiatry have established the existence of post-s

24 l-studied single-nucleotide polymorphisms in neuropsychiatry; however, findings are inconsistent due

25 Neuropsychiatry integrates neuroscience and clinical pat

26 s were assessed using the Mini-International Neuropsychiatry Interview, according to DSM-IV criteria.

27 rom the Schedules for Clinical Assessment in Neuropsychiatry interview.

28 strumental activities of daily living scale, neuropsychiatry inventory, and caregiver activity survey

29 Neuropsychiatry is the subspecialty of psychiatry that d

30 ew data from the behavioral neuroscience and neuropsychiatry literature on fear memory consolidation

31 This molecular approach to neuropsychiatry may assist in understanding the mechanis

32 es with the potential for greater insight in neuropsychiatry, neurooncology, and neurodegenerative di

33 erview (Schedules for Clinical Assessment in Neuropsychiatry or Psychiatric Assessment Schedule for A

34 al psychiatry and the power of the cognitive neuropsychiatry paradigm, its findings are logically con

35 f WHO's schedules for clinical assessment in neuropsychiatry (SCAN).

36 ing the Schedules for Clinical Assessment in Neuropsychiatry (SCAN).

37 earch in cognitive neuroscience and clinical neuropsychiatry.SIGNIFICANCE STATEMENT In recent years,

38 may expedite diagnosis and consultation with neuropsychiatry specialists for treatment of pediatric d

39 Many clinical syndromes in neuropsychiatry suggest focal brain activation.

40 its and (b) applying the current theories of neuropsychiatry to assess prognosis and to plan rehabili

41 polymorphisms at several loci of interest in neuropsychiatry-tryptophan hydroxylase (TPH), dopamine t

42 ovements in functioning after admission to a neuropsychiatry unit.

43 With the advent of brain banks in neuropsychiatry, we are now seeing postmortem neuroanato

44 ing the Schedules for Clinical Assessment in Neuropsychiatry, which incorporate the Present State Exa